NMS · Biotechnology

Lyell Immunopharma, Inc. (LYEL) Stock

$8.71 -0.91% NMS: LYEL Healthcare

Valuation

MetricValue
Price$8.71
Market Cap$213.43M
P/E Ratio-0.58
P/B Ratio0.93
P/S Ratio8404.09
EPS (TTM)$-16.06
52-Week High$45.00
52-Week Low$8.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-91.62%
ROA-79.86%
ROCE-70.80%
Gross Margin-74.23%
Operating Margin-6189.10%
Net Margin-7948.58%
Debt/Equity0.16
Current Ratio5.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$11.0M$85.0M$0$0$0
Operating Profit$-215.0M$-187.0M$-247.0M$-359.0M$-204.0M
Net Profit$-250.0M$-183.0M$-235.0M$-343.0M$-274.0M
EPS$-1.03$-0.74$-0.93$-1.31$-16.06
Op Margin-2016.7%-220.9%-190006.1%-588122.9%-566038.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$938.0M$750.0M$491.0M$340.0M
Total Liabilities$198.0M$104.0M$95.0M$108.0M$92.0M
Cash$294.0M$124.0M$146.0M$106.0M$60.0M
Borrowings$68.0M$68.0M$63.0M$59.0M$51.0M

Latest News

B. Riley Initiates Lyell Immunopharma at Buy With $44 Price Target MT Newswires · Jul 22, 2026 Lyell Immunopharma Files for Secondary Offering of Common Shares MT Newswires · Jul 13, 2026 AbCellera Appoints Dr. Lynn Seely to its Board of Directors Business Wire · Jul 6, 2026 Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet Zacks · Jul 2, 2026 Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-126.0M$-170.0M$-164.0M$-162.0M$-150.0M
Investing Cash Flow$-187.0M$-36.0M$181.0M$122.0M$53.0M
Financing Cash Flow$9.0M$0$0$0$0
Net Cash Flow$153.0M$-170.0M$22.0M$-39.0M$-46.0M
Free Cash Flow$-192.0M$-194.0M$-166.0M$-163.0M$-151.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.80
FCF Yield-59.04%
Quick Ratio5.36
Interest Coverage0.00
Return 1Y16.29%
Return 3Y-78.77%
Return 5Y-95.83%

Ownership

Insiders Held39.52%
Institutions Held56.86%
Institutions Float Held94.00%
Institutional HolderSharesReport Date
Arch Venture Management, Llc3,247,1622026-03-31
GSK plc1,512,6592026-03-31
Mwg Caph Ltd1,008,1162025-12-31
Foresite Capital Management IV, LLC800,3992026-03-31
Orland Properties Ltd.754,6982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIUAC Immune SA $2.50 -1.96% -5.24 $254.43M 0.00%
ALDXAldeyra Therapeutics, Inc. $0.92 -3.31% -3.02 $55.27M 0.00%
ALLOAllogene Therapeutics, Inc. $1.46 +4.29% -2.24 $503.93M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
CABACabaletta Bio, Inc. $1.93 -1.03% -1.27 $314.70M 0.00%

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. is led by CEO Lynn Seely, employs 300 people, headquartered in US, publicly traded since 2021.

Lyell Immunopharma, Inc. (LYEL) stock trades at $8.71 with a market capitalization of $213.43M. The stock is valued at a price-to-earnings (P/E) ratio of -0.58, price-to-book of 0.93, price-to-sales of 8404.09. Over the past 52 weeks the stock has ranged between $8.26 and $45.00, and currently trades 80.6% below its 52-week high.

On profitability, Lyell Immunopharma, Inc. generates a return on equity (ROE) of -91.62%, return on capital employed of -70.80%, an operating margin of -6189.10%, a net profit margin of -7948.58%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides